G194-0712 is a selective histone deacetylase 5 ( HDAC5 ) activator with an EC 50 of 7.96 μM and a K d of 2.53 μM. G194-0712 restores ACTN4-K417 deacetylation and nuclear import, and increases CSTA expression. G194-0712 accelerates wound closure in chronic wound models, reducing wound area and epithelial gap. G194-0712 can be used for the research of chronic skin wounds, such as diabetic wounds, ischemic wounds, radiation injury wounds [1].
In Vivo, G194-0712 (25 μM; topical application) accelerates diabetic wound healing in C57BLKS/J-db/db mice, ischemic wound healing and irradiated wound healing in C57BL/6J mice by reinstating ACTN4-K417 deacetylation, nuclear import, and CSTA expression, leading to reduced wound area and epithelial gap in and reduced wound area[1].
In Vitro, G194-0712 shows EC50 values of 107.2, 100.4 and 111.5 μM for HDAC4, HDAC7 and HDAC9[1].
References:
[1]. Zhang Y, et al. HDAC5 deacetylates cytosolic ACTN4 during skin reepithelialization and represents a therapeutic target for chronic wound healing. Sci Transl Med. 2025;17(830):eads0594.
In Vivo, G194-0712 (25 μM; topical application) accelerates diabetic wound healing in C57BLKS/J-db/db mice, ischemic wound healing and irradiated wound healing in C57BL/6J mice by reinstating ACTN4-K417 deacetylation, nuclear import, and CSTA expression, leading to reduced wound area and epithelial gap in and reduced wound area[1].
In Vitro, G194-0712 shows EC50 values of 107.2, 100.4 and 111.5 μM for HDAC4, HDAC7 and HDAC9[1].
References:
[1]. Zhang Y, et al. HDAC5 deacetylates cytosolic ACTN4 during skin reepithelialization and represents a therapeutic target for chronic wound healing. Sci Transl Med. 2025;17(830):eads0594.